George Canas, MD
Nephrology · Brooklyn Center, MNNPI 1922025774
Payments from drug & device makers
What this record shows
This record is dominated by education: $186 of the $229 with a category attached, or 81.2%. Otsuka America Pharmaceutical, Inc. accounts for 81.2% of it on its own, with 1 other manufacturer making up the rest.
Across 6 payments — averaging $38.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$186
- Daxor Corporation$43
Across 165 payments — averaging $12,557 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$651K
- Roche TCRC, Inc.$345K
- E.r. Squibb & Sons, L.L.C.$326K
- Incyte Corporation$281K
- Astellas Pharma Inc$245K
- Global Blood Therapeutics, Inc.$126K
- plus $98K from 2 others
What the payments were for
- Food & beverage$4319%
- Education$18681%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 4 | $186 |
| Daxor Corporation | 2 | $43 |
How this compares
$229 in reported general payments places this provider in the 60th percentile of 208 nephrology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VelphoroSucroferric Oxyhydroxide | 23 | $55,618 |
| VeltassaPatiromer Calcium Sorbitex | 18 | $17,421 |
| Lanthanum Carbonate | 14 | $13,461 |
| Sevelamer Carbonate | 126 | $9,198 |
| LokelmaSodium Zirconium Cyclosilicate | 33 | $5,070 |
| Midodrine Hcl | 81 | $4,772 |
| Calcium Acetate | 62 | $3,746 |
| Desmopressin Acetate | 15 | $1,729 |
| Potassium Chloride | 20 | $1,451 |
| Bumetanide | 21 | $1,304 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 39 | $1,247 |
| Carvedilol | 71 | $1,149 |
| Amlodipine Besylate | 93 | $999 |
| Allopurinol | 49 | $848 |
| Chlorthalidone | 28 | $738 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Brooklyn Center
- Orvin VisayaBrooklyn Center$4K
- Neera DahlRochester$102K
- Fernando FervenzaRochester$102K
- Kirsten JohansenMinneapolis$101K
- Jeffrey KohenMinneapolis$56K
- James WetmoreMinneapolis$48K
- Nelson LeungRochester$32K
- John LieskeRochester$31K
- Leticia RolonRochester$30K
- Prince SinghDuluth$26K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.